Ipca is a fully-integrated Indian pharmaceutical company that manufactures over 350 formulations and 80 active pharmaceutical ingredients (APIs) for various therapies. Ipca is a market leader in India in anti-malarials (over 34% market share), with a fast expanding presence internationally as well. They also lead in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for rheumatoid arthritis. They have leading brands in five pharmaceutical areas, with four of their branded formulations listed among the Top-300 Indian brands by ORG-IMS. The company serves over 110 countries, including markets in the U.S., Europe, Australia, Asia, and Africa. Their international client roster includes global pharmaceutical giants like AstraZeneca, GlaxoSmithKline, Merck, Roche and Sanofi Aventis
Mr. A. K. Jain joined the company as Financial Controller in 1980. He has over 30 years of experience including 29 years in the pharmaceutical industry in finance, accounts, information technology, legal, R&D, and general administration. Mr. Jain was first appointed to the board of directors of the company as an Executive Director in August 1994, and was re-designated as the Joint Managing Director of the Company in 2010.